Temsirolimus, an mTOR Inhibitor, to Reverse Androgen Insensitivity in Patients With Castration-resistant Prostate Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 18 Nov 2014
At a glance
- Drugs Temsirolimus (Primary) ; Bicalutamide
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 16 Jul 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
- 01 Apr 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.